[{"_1":2,"_3":-5,"_4":-5},"loaderData",{"_5":6,"_7":8},"actionData","errors","root",{"_96":97},"en-item",{"_9":10,"_10":11},"kind","item",{"_12":13,"_14":15,"_16":17,"_18":19,"_20":21,"_22":-5,"_23":24,"_25":26,"_27":28,"_29":30,"_31":30,"_32":33,"_34":35,"_36":37,"_38":39,"_40":41,"_42":43,"_44":45,"_46":-5,"_47":48,"_49":-5,"_50":-5,"_51":52,"_53":54,"_55":56,"_57":41,"_58":41,"_59":60,"_61":41,"_62":63},"id","algy4h3od0vu71zrnx19pr4yj","revision",2,"title","Ligand Pharmaceuticals 提交 Form 8-K，披露截至9月30日的三个月和九个月财务业绩公告","originalTitle","LIGAND PHARMACEUTICALS INC (0000886163) (Filer)","summary","Ligand Pharmaceuticals Incorporated 于10月29日提交 Form 8-K，称已发布截至9月30日的三个月和九个月财务业绩公告。公告作为附件99.1随报告提供；文件未列出具体业绩数据。","reason","source",{"_12":87,"_88":89,"_9":90,"_91":41,"_92":93,"_94":95},"links",{"_84":85,"_77":86},"publishedAt","2026-10-29T11:14:44.000Z","discoveredAt","2026-10-29T11:24:04.291Z","timelineAt","category","ai-products","tags",[82,83],"stockSymbols",[81],"score",19,"selected",true,"channel","news","story",{"_72":73,"_16":74},"x","readingMode","full","author","language","body",{"_63":76,"_77":-5,"_78":79,"_80":41},"outline",[],"relatedStories",[75],"indexable","markdownAvailable","group",{"_64":65,"_44":66,"_67":15,"_68":69,"_70":71},"hasTranslation","bodyLanguage","zh","factId","f_T-M_L9fFYk",{"_72":73,"_16":74},"reportCount","additionalSourceCount",1,"developmentCount",0,"publicId","d4ef0fb3-06b0-464c-b32d-d6d1771948a5","Ligand公布第三季度业绩并上调全年EPS指引",{"_72":73,"_16":74},"

美国

证券交易委员会

华盛顿特区 20549

______________

8-K 表格

______________

当前报告

根据《证券交易法》第 13 或 15(d) 条

1934 年《证券交易法》

报告日期（最早报告事件日期）：2026 年 10 月 29 日

LIGAND PHARMACEUTICALS INCORPORATED

（注册人章程中列明的确切名称）


特拉华州	001-33093	77-0160744
（州或其他司法管辖区	（委员会档案编号）	（美国国税局雇主
注册或组织地）		识别号）


555 Heritage Drive, Suite 200
Jupiter
佛罗里达州		33458
（主要行政办公室地址）		（邮政编码）

(858) 550-7500

（注册人电话号码，包括区号）

不适用

（自上次报告以来如有变更的前名称或前地址）

如果本 8-K 表格申报旨在同时履行注册人根据以下任何规定承担的申报义务，请勾选下面相应方框：

☐ 根据《证券法》第 425 条（17 CFR 230.425）进行的书面通信

☐ 根据《交易法》第 14a-12 条（17 CFR 240.14a-12）进行的征求材料

☐ 根据《交易法》第 14d-2(b) 条（17 CFR 240.14d-2(b））进行的开始前通信

☐ 根据《交易法》第 13e-4(c) 条（17 CFR 240.13e-4(c)）进行的开始前通信

根据第 12(b) 条注册的证券：


各类证券名称	交易代码	注册交易所名称
普通股，每股面值 $0.001	LGND	纳斯达克全球市场

请勾选以表明注册人是否为《1933 年证券法》第 405 条（本章 §230.405）或《1934 年证券交易法》第 12b-2 条（本章 §240.12b-2）所定义的新兴成长型公司。

新兴成长型公司 ☐

如果注册人为新兴成长型公司，请勾选以表明注册人是否选择不使用《交易法》第 13(a) 条规定的、遵守任何新订或修订财务会计准则的延长过渡期。 ☐

第 2.02 项经营业绩和财务状况。

2026 年 10 月 29 日，Ligand Pharmaceuticals Incorporated（“公司”）发布新闻稿，公布其截至 2026 年 9 月 30 日止三个月和九个月的财务业绩。本报告随附该新闻稿副本，作为附件 99.1 提交。

根据 Form 8-K 的一般指示 B.2，本 8-K 表格当前报告中的信息（包括附件 99.1）不得视为根据经修订的《1934 年证券交易法》（以下简称“《交易法》”）第 18 条“提交”，也不受该条规定的责任约束；除非某项文件明确通过具体引用作出规定，否则也不得视为通过引用纳入根据经修订的《1933 年证券法》或《交易法》提交的任何文件。

第 9.01 项财务报表及附件。

(d) 附件。


附件编号	说明
99.1	日期为 2026 年 10 月 29 日的新闻稿。

签名

根据经修订的《1934 年证券交易法》的要求，注册人已正式授权下列签署人代表其签署本报告。


	LIGAND PHARMACEUTICALS INCORPORATED

日期：2026 年 10 月 29 日	签署人： /s/ Andrew Reardon 姓名： Andrew Reardon 职务：首席法务官兼秘书

","original","zhKind","translation","complete","LGND","公司与财报","财报","aihot","/items/algy4h3od0vu71zrnx19pr4yj","https://www.sec.gov/Archives/edgar/data/886163/000088616326000058/0000886163-26-000058-index.htm","rss-sec-xbrl","name","SEC · EDGAR 财务披露","rss","firstParty","iconUrl","/api/img-proxy?u=https%3A%2F%2Fwww.sec.gov%2Fthemes%2Fcustom%2Fuswds_sec%2Fassets%2Fimg%2Ffavicons%2Fapple-touch-icon.png&mode=avatar&exp=1793664000&sig=2a69d6ab08599a1a","iconSrcSet","/api/img-proxy?u=https%3A%2F%2Fwww.sec.gov%2Fthemes%2Fcustom%2Fuswds_sec%2Fassets%2Fimg%2Ffavicons%2Fapple-touch-icon.png&mode=avatar-48&exp=1793664000&sig=c72c622a1dc90100 48w, /api/img-proxy?u=https%3A%2F%2Fwww.sec.gov%2Fthemes%2Fcustom%2Fuswds_sec%2Fassets%2Fimg%2Ffavicons%2Fapple-touch-icon.png&mode=avatar-96&exp=1793664000&sig=c831626a2a361459 96w","changelogVersion","2026-10-01T08:00"]